Relapsed Philadelphia chromosome‐positive B‐cell acute lymphoblastic leukaemia responds well to a combination of modified hyper‐CVAD, blinatumomab and tyrosine kinase inhibitor

Relapsed Philadelphia chromosome‐positive B‐cell acute lymphoblastic leukaemia responds well to a combination of modified hyper‐CVAD, blinatumomab and tyrosine kinase inhibitor

Abstract Introduction Adults with relapsed or refractory Philadelphia chromosome‐positive B‐cell precursor acute lymphoblastic leukaemia (R/R Ph+ BCP‐ALL) have a dismal outcome. Blinatumomab as a single agent has shown activity in R/R Ph‐ BCP‐ALL, and second or third‐generation tyrosine kinase inhib...

Full description

Saved in:
Bibliographic Details
Main Authors: Gaétan Basile, Jean Galtier, Titouan Cazaubiel, Edouard Forcade, Emilie Klein, Audrey Bidet, Carmen Botella‐Garcia, Clémence Mediavilla, Laurence Clement, Pierre‐Yves Dumas, Arnaud Pigneux, Thibaut Leguay
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:eJHaem
Subjects:
acute leukaemia
ALL
immunotherapy
tyrosine kinases
Online Access:https://doi.org/10.1002/jha2.1064
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/jha2.1064

Similar Items